CSPC PHARMA(01093),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01093 CSPC PHARMA

Trading 04-29 13:58:37

8.370

-0.040

-0.48%

High8.550	Low8.330	Vol48.28M
Open8.500	D1 Closing8.410	Amplitude2.62%
Mkt Cap96.44B	Tradable Cap96.44B	Total Shares11.52B
T/O405.75M	T/O Rate0.42%	Tradable Shares11.52B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"CSPC PHARMA","latestPrice":8.37,"timestamp":1777442312692,"preClose":8.41,"halted":0,"volume":48276748,"delay":0,"changeRate":-0.004756242568371097,"floatShares":11522000000,"shares":11522000000,"eps":0.3398,"marketStatus":"Trading","change":-0.04,"latestTime":"04-29 13:58:37","open":8.5,"high":8.55,"low":8.33,"amount":405753395,"amplitude":0.026159,"askPrice":8.38,"askSize":648000,"bidPrice":8.37,"bidSize":104000,"shortable":3,"etf":0,"ttmEps":0.378133,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777450200000},"marketStatusCode":2,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":8.41,"dividendRate":0.035822,"openAndCloseTimeList":[[1777426200000,1777435200000],[1777438800000,1777449600000]],"volumeRatio":0.870529,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":true,"expireDate":1785340800000,"strike":"12.50","timestamp":1777432685655,"price":0.08,"volume":340,"amount":54400,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.473,"impliedVolPercentile":0.1504},"requestUrl":"/m/hq/s/01093/tweets","defaultTab":"tweets","newsList":[{"id":"1120394652","title":"CSPC PHARMA 2025年绩效：收入下滑10.4%至260.06亿元，主营业务分化下分红逆势增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1120394652","media":"Bulletin Express","labels":["dataReport","SGX"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1120394652?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:47","pubTimestamp":1777376852,"startTime":"0","endTime":"0","summary":"根据CSPC...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CSPC PHARMA 2025年绩效：收入下滑10.4%至260.06亿元，主营业务分化下分红逆势增加","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137081614","title":"CSPC Pharma Publishes 2025 Annual Report, AGM Materials and ESG Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1137081614","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137081614?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:27","pubTimestamp":1777379269,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has released the following corporate documents for the financial year ended 2025: 1. 2025 Annual Report   2. Circular, Notice of Annual General Meeting...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116874573","title":"CSPC Showcases 2025 ESG Progress: RMB 5.81 Billion R&D Spend, 200+ Innovative Drugs in Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1116874573","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116874573?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:48","pubTimestamp":1777376918,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited (CSPC) released its 2025 Environmental, Social and Governance Report, detailing expanded R&D investment, strengthened quality controls and accelerated...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181549777","title":"CSPC Pharmaceutical Plans 10% Buyback Mandate, Tightens Issuance Discount and Seeks Share Option Refresh","url":"https://stock-news.laohu8.com/highlight/detail?id=1181549777","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181549777?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:44","pubTimestamp":1777376697,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group has released its 2026 AGM circular outlining several capital management and governance proposals. Key items will be voted on at the meeting scheduled for 28 May 2026 in Hong...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119862202","title":"CSPC Pharma Requests Shareholder Preference for Electronic or Printed Corporate Communications, Releases 2025 ESG Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1119862202","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119862202?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:44","pubTimestamp":1777376695,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has issued a notice to newly registered shareholders requesting selection of preferred formats—electronic or printed—for all future corporate...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630309317","title":"CSPC Pharmaceutical Group announces annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630309317","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630309317?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:43","pubTimestamp":1777376622,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group will hold its annual general meeting in Wan Chai, Hong Kong on May 28, 2026.Shareholders will vote on receiving 2025 audited financial statements and related reports.Final dividend of HK 0.15 per share for year ended Dec. 31, 2025 is slated for approval.Resolutions include re-election of directors, re-appointment of Deloitte Touche Tohmatsu as auditor, mandates to buy back shares or issue new shares, adoption of a new share option scheme.Meeting will also vote on adopting new articles of association.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL7Wkp7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","LU1960683339.HKD","HK0000165453.HKD","IE0008368742.USD","BK1515","LU1152091168.USD","LU1951186391.HKD","BK1191","LU1226287875.USD","LU1813983027.USD","LU1328277881.USD","LU0067412154.USD","LU1993786604.SGD","LU0326950275.SGD","LU0880133367.SGD","LU0140636845.USD","LU1152091754.HKD","IE00B543WZ88.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU0315179316.USD","LU1008478684.HKD","LU0072913022.USD","LU1807302812.USD","BK1521","LU2039709279.SGD","LU0314109678.HKD","IE00B5MMRT66.SGD","LU1226287529.USD","LU1226287792.SGD","LU1226288170.HKD","LU0501845795.SGD","IE00B031HY20.USD","SG9999004220.SGD","IE00BZ08YR35.GBP","IE0008369823.USD","LU1226288253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172364466","title":"CSPC PHARMA releases 2025 Annual Report, AGM Circular and ESG Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1172364466","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172364466?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:43","pubTimestamp":1777376619,"startTime":"0","endTime":"0","summary":"On 29 April 2026, CSPC Pharmaceutical Group Limited (CSPC PHARMA) announced the official publication of its 2025 Annual Report, the accompanying AGM circular, notice of annual general meeting, proxy...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630230621","title":"CSPC Pharmaceutical publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630230621","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630230621?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:37","pubTimestamp":1777376270,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical released its 2025 annual report, highlighting pressure on finished-drug sales from China volume-based procurement while shifting emphasis toward innovation-led growth.International business development accelerated, with five out-licensing deals signed since early 2025 totaling contract value of USD 28.21 billion.R&D activity expanded, with 14 manufacturing approvals, 73 clinical trial approvals, and five Breakthrough Therapy Designations recorded during 2025.Pipeline progress supported new commercial momentum, including continued uptake of stroke therapy Mingfule and launches that broadened exposure to autoimmune, metabolic, and oncology markets.Capital returns increased, with HKD 300 million used to repurchase and cancel 64,300,000 shares in 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL1VP8kd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072913022.USD","LU1152091754.HKD","01093","LU1226287875.USD","LU1226287529.USD","IE0008368742.USD","LU0140636845.USD","LU1226288170.HKD","LU1807302812.USD","LU1328277881.USD","HK0000165453.HKD","LU1226287792.SGD","LU0501845795.SGD","LU2039709279.SGD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU0315179316.USD","LU1152091168.USD","IE00BZ08YT58.USD","SG9999004220.SGD","BK1521","LU1960683339.HKD","IE00BZ08YS42.EUR","LU0314109678.HKD","LU1226288253.USD","LU1008478684.HKD","LU1993786604.SGD","LU0067412154.USD","LU1951186391.HKD","LU0326950275.SGD","IE0008369823.USD","LU0880133367.SGD","LU1813983027.USD","IE00B543WZ88.USD","BK1191","IE00B031HY20.USD","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111096213","title":"Stock Track | CSPC Pharma Plummets 5.11% Intraday on Subsidiary's Widening Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1111096213","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111096213?lang=en_us&edition=fundamental","pubTime":"2026-04-28 14:39","pubTimestamp":1777358385,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group's stock plummeted 5.11% during Tuesday's intraday trading session, following the disclosure of weak quarterly results from its subsidiary, CSPC Innovation Pharmaceutical.The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167969663","title":"CSPC PHARMA Subsidiary Reports Widened Net Loss in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=1167969663","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167969663?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:26","pubTimestamp":1777292799,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) announced that its subsidiary, CSPC Innovation, recorded revenue of RMB 665 million in the first quarter of 2026, representing a year-on-year increase of 40.82%. However, the net...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","BK1191","LU1226287529.USD","IE00B031HY20.USD","LU1951186391.HKD","IE0008368742.USD","LU1226287792.SGD","SG9999004220.SGD","LU1152091754.HKD","LU2039709279.SGD","LU0880133367.SGD","LU0326950275.SGD","LU1807302812.USD","BK1515","LU0501845795.SGD","IE0008369823.USD","LU1008478684.HKD","LU1813983027.USD","LU1993786604.SGD","LU1226287875.USD","LU1226288253.USD","IE00B543WZ88.USD","IE00BZ08YT58.USD","HK0000165453.HKD","LU1226288170.HKD","LU0315179316.USD","IE00BZ08YR35.GBP","LU0067412154.USD","01093","LU1152091168.USD","LU1960683339.HKD","IE00BZ08YS42.EUR","BK1521","LU1328277881.USD","LU0072913022.USD","LU0140636845.USD","LU0314109678.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116208912","title":"CSPC Innovation Q1 2026 Revenue Jumps 40.82%, Net Loss Deepens on R&D Spend and FX Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=1116208912","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116208912?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:24","pubTimestamp":1777292664,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical Co., Ltd. (a subsidiary of CSPC PHARMA) reported unaudited results for the three months ended 31 March 2026, prepared under China Accounting Standards for Business...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630960883","title":"CSPC Innovation posts Q1 net loss of RMB 93.85 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2630960883","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630960883?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:11","pubTimestamp":1777291918,"startTime":"0","endTime":"0","summary":"CSPC Innovation, CSPC Pharmaceutical Group subsidiary, posted Q1 2026 revenue of RMB 664.65 million, up 40.82% year on year.Net loss attributable to shareholders widened to RMB 93.85 million from RMB 26.9 million.Operating cash outflow increased to RMB 179.52 million from RMB 86.8 million.Megalith Biopharma consolidation scope expanded as shareholding rose to 80% from 51%, driving higher R&D spending.Revenue growth reflected functional ingredients, biopharmaceutical products, recognition of US$ 10 million milestone revenue tied to SYS6002 out-licensing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service ope","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL9yvCmQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU1993786604.SGD","LU1813983027.USD","LU0326950275.SGD","01093","IE0008368742.USD","LU1226287792.SGD","LU1226288253.USD","IE0008369823.USD","LU0140636845.USD","BK1521","LU1807302812.USD","LU1152091754.HKD","LU1951186391.HKD","LU1328277881.USD","LU0067412154.USD","LU1226287529.USD","LU0315179316.USD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU2039709279.SGD","BK1191","IE00BZ08YT58.USD","SG9999004220.SGD","HK0000165453.HKD","LU1226287875.USD","300765","LU0880133367.SGD","LU1152091168.USD","IE00B031HY20.USD","LU1008478684.HKD","BK0226","LU0314109678.HKD","LU0501845795.SGD","BK1515","LU0072913022.USD","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396432","title":"CSPC Pharmaceutical - Q1 Net Loss Attributable RMB 93.9 Mln for CSPC Innovation Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396432?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:04","pubTimestamp":1777291464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN41A0K7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01093","IE00B031HY20.USD","LU0315179316.USD","LU1813983027.USD","LU1226288253.USD","BK1191","LU0501845795.SGD","LU0140636845.USD","LU0880133367.SGD","SG9999004220.SGD","LU1993786604.SGD","LU0072913022.USD","LU1226287529.USD","IE00B5MMRT66.SGD","LU1152091168.USD","IE00BZ08YS42.EUR","LU1226287875.USD","LU1807302812.USD","BK1515","IE0008368742.USD","IE0008369823.USD","BK0226","LU0314109678.HKD","LU1226287792.SGD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1521","LU1226288170.HKD","300765","LU0067412154.USD","IE00B543WZ88.USD","LU0326950275.SGD","LU1951186391.HKD","LU2039709279.SGD","LU1152091754.HKD","LU1960683339.HKD","LU1008478684.HKD","LU1328277881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630836634","title":"CSPC Pharmaceutical Group Stock Sheds 1.9% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2630836634","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630836634?lang=en_us&edition=fundamental","pubTime":"2026-04-27 16:32","pubTimestamp":1777278720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. shed 1.9% to 8.81 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.2% to 25925.65.The stock's fall snapped a two-day winning streak.CSPC Pharmaceutical Group Ltd. closed 24% short of its 52-week high of HK$11.63, which the company achieved Sept. 9.Despite its losses, the stock outperformed some of its competitors, as Sino Biopharmaceutical Ltd. fell 2.5%, SSY Group Ltd. fell 2.1%, and United Laboratories International Holdings Ltd. fell 3.1%.Trading volume totaled 53.3 million shares, compared to the 50-day average of 88.4 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287875.USD","BK1191","IE00BZ08YS42.EUR","LU1152091168.USD","LU0067412154.USD","IE00B543WZ88.USD","LU0072913022.USD","LU0314109678.HKD","BK1515","LU0326950275.SGD","LU1226288170.HKD","SG9999004220.SGD","LU1328277881.USD","LU1993786604.SGD","LU1226287792.SGD","IE00B031HY20.USD","LU2039709279.SGD","LU1807302812.USD","LU0315179316.USD","LU1226288253.USD","LU1226287529.USD","LU1960683339.HKD","BK1521","IE00B5MMRT66.SGD","IE0008369823.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU0140636845.USD","01093","IE00BZ08YR35.GBP","LU1951186391.HKD","LU1152091754.HKD","LU1813983027.USD","HK0000165453.HKD","IE0008368742.USD","LU0501845795.SGD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630826398","title":"Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After Key PEComa Trial Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2630826398","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630826398?lang=en_us&edition=fundamental","pubTime":"2026-04-24 23:11","pubTimestamp":1777043509,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (SEHK:1093) has flagged a key product milestone after its subsidiary reported that a Phase Ib/III trial of Sirolimus for Injection in advanced malignant PEComa met its primary efficacy endpoint in China.\nSee our latest analysis for CSPC Pharmaceutical Group.\nThe HB1901 trial news sits alongside a mixed share price picture, with CSPC Pharmaceutical Group’s HK$8.98 latest close coming after a 5.8% year to date share price return but an 8.5% 3 month share price decline,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/assessing-cspc-pharmaceutical-group-sehk1093-valuation-after-4","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/assessing-cspc-pharmaceutical-group-sehk1093-valuation-after-4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B543WZ88.USD","BK1521","LU2039709279.SGD","IE00B031HY20.USD","LU1152091168.USD","IE0008369823.USD","LU0880133367.SGD","IE0008368742.USD","LU1008478684.HKD","LU1226288253.USD","LU1328277881.USD","LU0140636845.USD","LU0314109678.HKD","LU0501845795.SGD","01093","LU1807302812.USD","IE00BZ08YT58.USD","HK0000165453.HKD","LU1226287792.SGD","LU0067412154.USD","LU1226287875.USD","LU0315179316.USD","LU1226287529.USD","LU0326950275.SGD","IE00B5MMRT66.SGD","LU0072913022.USD","LU1993786604.SGD","LU1152091754.HKD","BK1515","SG9999004220.SGD","LU1951186391.HKD","LU1226288170.HKD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1813983027.USD","BK1191","DCF","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114117750","title":"CSPC Pharma Receives U.S. FDA Clearance to Begin Clinical Trials for First-in-Class KAT6 Inhibitor SYH2095","url":"https://stock-news.laohu8.com/highlight/detail?id=1114117750","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114117750?lang=en_us&edition=fundamental","pubTime":"2026-04-24 20:45","pubTimestamp":1777034737,"startTime":"0","endTime":"0","summary":"On 24 April 2026, CSPC Pharmaceutical Group Limited (CSPC Pharma) announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for SYH2095...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106188578","title":"CSPC PHARMA's Novel KAT 6 Inhibitor Receives FDA Clearance for U.S. Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1106188578","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106188578?lang=en_us&edition=fundamental","pubTime":"2026-04-24 19:42","pubTimestamp":1777030955,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) announced that SYH2095 tablets, a new Class 1 chemical drug developed in collaboration with Hangzhou Yingchuang Medicine Technology Co., Ltd., have received approval from the U.S....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","KAT","LU1951186391.HKD","LU1328277881.USD","LU1807302812.USD","IE0008369823.USD","LU0140636845.USD","IE00BZ08YR35.GBP","LU1226287529.USD","LU0326950275.SGD","LU0072913022.USD","HK0000165453.HKD","IE00BZ08YT58.USD","LU0501845795.SGD","LU1226288170.HKD","IE00B543WZ88.USD","LU1226287792.SGD","BK1515","LU0314109678.HKD","LU0067412154.USD","LU0880133367.SGD","LU0315179316.USD","LU1226288253.USD","IE0008368742.USD","BK1191","BK1521","LU1152091168.USD","LU1813983027.USD","SG9999004220.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","LU2039709279.SGD","LU1993786604.SGD","LU1960683339.HKD","LU1008478684.HKD","01093","LU1152091754.HKD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629845161","title":"CSPC says FDA clears US clinical trial for KAT6 inhibitor SYH2059 tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2629845161","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629845161?lang=en_us&edition=fundamental","pubTime":"2026-04-24 19:38","pubTimestamp":1777030730,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group received FDA clearance to start U.S. clinical trials for SYH2059 tablets, a highly selective KAT6 inhibitor for advanced malignant tumors.CSPC said no KAT6-targeting drug has been approved for sale in China or overseas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL3fl53x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287875.USD","BK1191","IE00BZ08YS42.EUR","LU1152091168.USD","LU0067412154.USD","IE00B543WZ88.USD","LU0072913022.USD","LU0314109678.HKD","BK1515","LU0326950275.SGD","LU1226288170.HKD","SG9999004220.SGD","LU1328277881.USD","LU1993786604.SGD","LU1226287792.SGD","IE00B031HY20.USD","LU2039709279.SGD","LU1807302812.USD","LU0315179316.USD","LU1226288253.USD","LU1226287529.USD","LU1960683339.HKD","BK1521","IE00B5MMRT66.SGD","IE0008369823.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU0140636845.USD","01093","IE00BZ08YR35.GBP","LU1951186391.HKD","LU1152091754.HKD","LU1813983027.USD","HK0000165453.HKD","IE0008368742.USD","LU0501845795.SGD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629451638","title":"CSPC Pharmaceutical - Syh2095 Tablets Obtain FDA Approval for U.S. Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2629451638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629451638?lang=en_us&edition=fundamental","pubTime":"2026-04-24 19:38","pubTimestamp":1777030695,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nFWN41704Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BZ08YT58.USD","IE0008369823.USD","SG9999004220.SGD","LU1226288253.USD","IE00B5MMRT66.SGD","LU0315179316.USD","LU0314109678.HKD","LU1226287875.USD","LU1951186391.HKD","LU1993786604.SGD","LU0140636845.USD","01093","LU1813983027.USD","LU1008478684.HKD","LU1960683339.HKD","BK1521","IE00BZ08YR35.GBP","HK0000165453.HKD","LU1807302812.USD","LU1328277881.USD","IE00BZ08YS42.EUR","BK1191","LU1226287792.SGD","LU0501845795.SGD","LU2039709279.SGD","IE00B543WZ88.USD","LU0067412154.USD","LU1226287529.USD","LU0326950275.SGD","LU1152091168.USD","IE0008368742.USD","LU0072913022.USD","LU0880133367.SGD","BK1515","LU1152091754.HKD","LU1226288170.HKD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629015159","title":"CSPC Pharmaceutical Group Stock Sheds 2.2% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2629015159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629015159?lang=en_us&edition=fundamental","pubTime":"2026-04-22 16:33","pubTimestamp":1776846780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slid 2.2% to 8.77 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.2% to 26163.24.This was the stock's second consecutive day of losses.CSPC Pharmaceutical Group Ltd. closed 25% below its 52-week high of HK$11.63, which the company reached Sept. 9.The stock underperformed when compared to some of its competitors, as Sino Biopharmaceutical Ltd. rose 0.2%, SSY Group Ltd. fell 1.2%, and United Laboratories International Holdings Ltd. fell 1.8%.Trading volume totaled 110.5 million shares, compared to the 50-day average of 90.9 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","IE0008369823.USD","IE00B031HY20.USD","LU0315179316.USD","LU1960683339.HKD","LU1226288253.USD","SG9999004220.SGD","LU0314109678.HKD","BK1191","LU1993786604.SGD","LU1807302812.USD","LU1008478684.HKD","LU1226287875.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU0880133367.SGD","IE0008368742.USD","LU0501845795.SGD","LU1152091168.USD","IE00BZ08YT58.USD","LU0072913022.USD","HK0000165453.HKD","IE00B543WZ88.USD","BK1521","01093","LU1226288170.HKD","LU1226287529.USD","LU2039709279.SGD","IE00B5MMRT66.SGD","LU1813983027.USD","IE00BZ08YR35.GBP","LU1328277881.USD","LU1951186391.HKD","LU0140636845.USD","LU0326950275.SGD","LU0067412154.USD","LU1152091754.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0624},{"period":"1month","weight":-0.0947},{"period":"3month","weight":-0.2028},{"period":"6month","weight":0.1258},{"period":"1year","weight":0.432},{"period":"ytd","weight":-0.0024}],"compareEarnings":[{"period":"1week","weight":-0.0305},{"period":"1month","weight":0.0292},{"period":"3month","weight":-0.0772},{"period":"6month","weight":-0.0229},{"period":"1year","weight":0.1688},{"period":"ytd","weight":0.0019}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094687},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017323},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057765},{"month":5,"riseRate":0.612903,"avgChangeRate":0.047434},{"month":6,"riseRate":0.322581,"avgChangeRate":0.003636},{"month":7,"riseRate":0.375,"avgChangeRate":0.009082},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010009},{"month":9,"riseRate":0.5,"avgChangeRate":0.000153},{"month":10,"riseRate":0.5625,"avgChangeRate":0.010484},{"month":11,"riseRate":0.46875,"avgChangeRate":0.00638},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013271}],"exchange":"SEHK","name":"CSPC PHARMA","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CSPC PHARMA(01093),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CSPC PHARMA(01093) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CSPC PHARMA,01093,CSPC PHARMA股票,CSPC PHARMA股票老虎,CSPC PHARMA股票老虎国际,CSPC PHARMA行情,CSPC PHARMA股票行情,CSPC PHARMA股价,CSPC PHARMA股市,CSPC PHARMA股票价格,CSPC PHARMA股票交易,CSPC PHARMA股票购买,CSPC PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CSPC PHARMA(01093),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CSPC PHARMA(01093) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}